Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it has received notification for the exercise of a warrant over 347,915 ordinary shares in the Company at an exercise price of 76 pence per share providing the Company with proceeds of £264,415 ("Warrant Exercise").
Application has been made to the London Stock Exchange to admit the 347,915 new ordinary shares resulting from the Warrant Exercise to trading on AIM (“Admission”), which is expected to occur on 16 June 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above and including the 10,437,000 Firm Placing shares to be issued in connection with the Firm Placing announced yesterday by the Company, on 16 June 2020 the Company’s issued share capital admitted to trading on AIM will comprise 80,367,992 ordinary shares of 0.2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.